Universal HPLC detector offers near nanogram sensitivity

Published: 6-May-2010
Manufacturing Research & Development Analysis

NQAD is said to be a major advance in high-performance liquid chromatography detection

Dorton Analytical, a UK supplier of laboratory equipment, says its ultra-sensitive, universal Nano Quantity Analyte Detector (NQAD) is a major advance in high-performance liquid chromatography detection.

The NQAD is a different kind of aerosol-based detector for HPLC, the company says. Based on Condensation Nucleation (CNLSD) technology, the NQAD has the ability to detect sub-nanogram levels.

Benefiting from ultra-high sensitivity, the detector is suitable for searching for drug impurities, degradation products, excipients and when industrial hygiene is a concern. Both easy and hard-to-measure compounds can be quantified accurately with minimal sample preparation, the company says.

The NQAD detector also offers a wide dynamic range with superior linearity compared with other aerosol-based detectors. Chromophores and fluorophores are not needed for detection, thereby eliminating or decreasing the need for compound derivatisation. The detector is optimised for use in UHPLC, HPLC and SFC.

The company says it is easy to install and operate and therefore ideal for use in any laboratory.

See more

You may also like

Manufacturing

Setting standards for polymer and protein characterisation

Read more
SEC-3010 triple detector system uses GPC/SEC

Trending Articles

  1. Stipple Bio enters into multi-target license agreement with Lonza to advance precision oncology ADC therapies Stipple Bio’s Pointillist Platform identifies tumour-specific cell surface epitopes that, when combined with Lonza’s clinically validated ADC platform, may enable first-in-class and best-in-class ADC oncology medicines such as STP-100
  2. Compact, economical and sustainable cooling solutions for laboratories Huber Unichillers offer space-saving and environmentally friendly temperature control for research and industrial applications
  3. Lonza advances integrated DNA‑to‑IND programmes with acceleration, derisking and innovation New GS Ori‑Go vector technology supports titers higher than 11 g/L and reliable bulk pool stability, enabling more predictable material generation and shortened cell line development timelines
  4. Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb as part of ongoing strategic collaboration CRDMO successfully scaled and transferred Renaissance Pharma’s lead candidate, Daretabart a humanised monoclonal antibody targeting GD2 for high-risk neuroblastoma, in just 9 months

Upcoming event

BIO International Convention

22–25 June 2026 | Convention | Boston, US See all

You may also like

Manufacturing

Setting standards for polymer and protein characterisation

SEC-3010 triple detector system uses GPC/SEC
Manufacturing

Lonza appoints Hans Trees as Global Head of Communications

Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing

AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn

AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Ingredients

Safe and accurate flow measurement for pharmaceutical production

Oval Gear (OG) meters from Titan Enterprises, fitted with a Namur sensor, provide consistent, accurate measurement across a wide range of liquids, from low-viscosity solvents to more viscous pharmaceutical ingredients
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

The path to commercial allogeneic iPSC therapies

The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Manufacturing

Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference

By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
Research & Development

The IND advantage: why early derisking is a strategic imperative for complex biologics

As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Subscribe now